Home
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant

Today’s Highlights December 7, 2021

GlaxoSmithKline and Vir Biotechnology Sotrovimab Retains In Vitro Activity Against Omicron
GlaxoSmithKline plc (GSK) and Vir Biotechnology (This content is for paid subscribers.

Please click here to subscribe or here to log in.
Today’s Highlights
, ,
December 7, 2021

Other Articles